Finanzen von Inhibikase Therapeutics Inc (IKT)IKTInhibikase Therapeutics Inc

Evaluating the bottom line, Inhibikase Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -51.96%, provide a clear picture of how effectively IKT converts its operational activities into shareholder value.

In the context of the broader market, IKT competes directly with industry leaders such as PYXS and SIGA. With a market capitalization of $218.38M, it holds a significant position in the sector. When comparing efficiency, IKT's gross margin of N/A stands against PYXS's N/A and SIGA's 57.17%. Such benchmarking helps identify whether Inhibikase Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Inhibikase has reported net income losses consistently, with Q2 2026 showing a loss of -$19,591,231. The EPS for the last quarter was -0.11, indicating ongoing challenges in achieving profitability. The company's cash position is relatively strong at $170.4 million, which provides some buffer for operations and R&D.